Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01484977 · ClinicalTrials.gov registry record · Phase 3
eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT01484977 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 120 participants.
The verdict
NCT01484977, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel blocking-antiepileptic drug (AEDs) in subjects not well controlled on their current regimen.
Interventions
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01484977
The ClinicalTrials.gov registry entry for NCT01484977 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lacosamide is the first listed.
NCT01484977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01484977 about?
NCT01484977 is a clinical study titled "eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam". The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel blocking-antiepileptic drug (AEDs) in subjects not well controlled on their ...
What is the current status of trial NCT01484977?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2011-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01484977?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT01484977?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.